Revvity Inc Hits 20-Day High
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 25 Nov 25
Source: 8-K
Revvity Inc has reached a significant milestone by hitting a 20-day high in its stock price. This upward movement of +5.12% reflects positive market sentiment towards the company.
The broader market is currently trading sideways, with major benchmarks showing mixed signals. Despite this lack of clear direction, Revvity's performance stands out, indicating strong investor interest.
Technical indicators suggest that this rise could be part of a larger trend, as the stock has shown resilience in a fluctuating market environment. Investors are closely monitoring Revvity for potential further gains.
Analyst Views on RVTY
Wall Street analysts forecast RVTY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RVTY is 113.38 USD with a low forecast of 105.00 USD and a high forecast of 123.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
6 Buy
4 Hold
0 Sell
Moderate Buy
Current: 111.130
Low
105.00
Averages
113.38
High
123.00
Current: 111.130
Low
105.00
Averages
113.38
High
123.00
About RVTY
Revvity, Inc. is a provider of health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. The Company has specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more. Its segments include Life Sciences and Diagnostics. The Life Sciences segment provides products and services targeted towards the life sciences market. The segment offers instruments, reagents, software, detection and imaging technologies, and others. The Diagnostics segment develops diagnostics, tools, and applications focused on clinically oriented customers, within the reproductive health, immunodiagnostics, and applied genomics markets. The segment offers instruments, reagents, assay platforms and software to hospitals, medical labs, clinicians and medical research professionals to help improve the health of families.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
